The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.

Washington

District of Columbia

United States

Drugmakers and pharmacists battle over who gets to make obesity drugs

Ad Fontes Media

All Sides

Media Bias/Fact Check

National Public Radio, Inc

KPBS

California State University

thepublicsradio.org

Drugmakers and pharmacists battle over who gets to make obesity drugs - TPR: The Public's Radio

GLP-1s like the weight-loss drug Wegovy can be made by compounding pharmacies while they’re in short supply. Drugmakers argue they no longer are.                      James Manning/PA Images/Getty Images                          James Manning/PA Images/Getty Images Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high demand that the drugmakers have had a hard time keeping up. So compounding pharmacies stepped in to fill…

Busines and Oil News

Drugmakers and pharmacists battle over who gets to make obesity drugs – DG Verifications & Stats

(NPR) – The compounded versions are especially popular as cheaper alternatives for people whose insurance doesn’t cover them. But now the brand name manufacturers are pushing the compounding pharmacies to stop. Novo Nordisk and Eli Lilly are moving to end compounding of their medicines for good. They say they are no longer in shortage (a necessary condition for legal compounding in this case), and that they are too difficult to compound anyway. …

Bioethics.com

Wegovy

Ozempic

Drugmakers and pharmacists battle over who gets to make obesity drugs

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics